Logotype for DiaMedica Therapeutics Inc

DiaMedica Therapeutics (DMAC) investor relations material

DiaMedica Therapeutics Cantor Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for DiaMedica Therapeutics Inc
Cantor Global Healthcare Conference 2025 summary4 Sep, 2025

Key program updates and clinical data

  • Successfully manufactured recombinant tissue kallikrein, overcoming challenges faced by others in the field.

  • Recent phase II data in preeclampsia showed significant blood pressure reductions and no placental transfer of DM199.

  • Drug demonstrated a 25 mmHg drop in systolic and 13 mmHg in diastolic blood pressure, with a 13% reduction in pulsatility index, indicating improved placental perfusion.

  • Safety profile was favorable, with no increase in fetal heart rates and no DM199 detected in cord blood.

  • Early evidence suggests potential for disease modification by improving endothelial health and uterine artery dilation.

Market opportunity and unmet need

  • Preeclampsia represents a $5+ billion market in the U.S. with 180,000–250,000 cases annually; focus is on the 30,000 early-onset cases before 34 weeks gestation.

  • Current treatments are limited, often only delaying delivery by about a week, and many antihypertensives are contraindicated in pregnancy.

  • Every additional day of gestation can significantly reduce neonatal mortality and long-term complications.

  • Orphan-like pricing is anticipated due to the high unmet need and cost savings from reduced NICU stays and long-term care.

Mechanism of action and differentiation

  • DM199 is a recombinant tissue kallikrein, distinct from plasma kallikrein, and does not interact with the fibrinolytic or complement systems.

  • The drug increases blood flow and oxygenation to the placenta, potentially addressing the root cause of preeclampsia.

  • Similar proteins are used in Asia for stroke and hypertension, but DM199 is a recombinant, purified form.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next DiaMedica Therapeutics earnings date

Logotype for DiaMedica Therapeutics Inc
Q3 202513 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next DiaMedica Therapeutics earnings date

Logotype for DiaMedica Therapeutics Inc
Q3 202513 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious diseases, with an emphasis on acute ischemic stroke (AIS) and cardio-renal diseases. The company is dedicated to improving patient outcomes by advancing its lead product candidate, DM199, which is a synthetic version of the human tissue kallikrein-1 (KLK1) protein. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage